APhA NOMINATES GREEN AND VALENTINE AS CANDIDATES FOR CHAIRPERSON-ELECT
APhA NOMINATES GREEN AND VALENTINE AS CANDIDATES FOR CHAIRPERSON-ELECT of the 1987 American Pharmaceutical Association (APhA) Board of Trustees. The APhA nominations committee made its selections for the 1987-1989 board at its Aug. 14 meeting, and election ballots will be mailed to APhA active members by the end of September. Charles Green is president of Green Brothers Pharmacy, Inc. and Home Medical Supply, Inc., of Stockton, California. He is a past president of the California Pharmacists Association and has served as an APhA Trustee since 1984. E. Michelle Valentine is a community pharmacist in Everett, Washington. She has served as speaker of the Washington State Pharmaceutical Association Senate, project director of APhA's Project SPEED, vice-speaker of the APhA House of Delegates, and has been an APhA Trustee since 1984. The winning candidate will succeed to the office of chairperson of the board in 1988. D. Stephen Crawford of Elkins, West Virginia, currently serving as chairperson-elect, will replace James Main as APhA Board of Trustees chairperson on Jan. 1, 1987. The nominations committee also selected three pairs of candidates to serve 1987-1989 terms on the APhA board. Members will vote for one candidate from each pair. The board candidates are Thomas Garrison, Missouri, and Raymond Roberts, Florida (Pair I); J. Lyle Bootman, Arizona, and Marcellus Grace, Louisiana (Pair II); and Jerry Moore, Alabama, and Robert Osterhaus, Iowa (Pair III).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth